Medifast Inc. (MED) reported fourth-quarter 2025 revenue of $75.1 million, down 36.9% year-over-year and slightly above the consensus revenue estimate of $74.5 million.
Cost of sales totaled $23.0 million, contributing to the compression in gross profit.
In short, Medifast (MED) posted a modest revenue beat but a widening operating and net loss, with EPS falling well below expectations; liquidity remains around $89.3 million while liabilities have declined.
Note: This financials data is sourced from a third-party provider and has not been independently verified by Quiver.
MEDIFAST INC Hedge Fund Activity
We have seen 38 institutional investors add shares of MEDIFAST INC stock to their portfolio, and 86 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- BANK OF AMERICA CORP /DE/ removed 355,070 shares (-78.5%) from their portfolio in Q4 2025, for an estimated $3,792,147
- STEAMBOAT CAPITAL PARTNERS, LLC added 276,414 shares (+inf%) to their portfolio in Q4 2025, for an estimated $2,952,101
- MORGAN STANLEY removed 253,681 shares (-43.1%) from their portfolio in Q4 2025, for an estimated $2,709,313
- ACADIAN ASSET MANAGEMENT LLC removed 239,664 shares (-60.3%) from their portfolio in Q4 2025, for an estimated $2,559,611
- CHARLES SCHWAB INVESTMENT MANAGEMENT INC added 181,618 shares (+30.5%) to their portfolio in Q4 2025, for an estimated $1,939,680
- AQR CAPITAL MANAGEMENT LLC removed 179,310 shares (-57.7%) from their portfolio in Q4 2025, for an estimated $1,915,030
- TWO SIGMA INVESTMENTS, LP removed 148,459 shares (-64.9%) from their portfolio in Q4 2025, for an estimated $1,585,542
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
